Priority Report: ASCO 2022: Updates in Genetic Testing

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of helping patients make informed decisions about their care options and the future role of antibody-drug conjugate targets in the biomarker testing arena.

Genetic testing has afforded oncologists with the opportunity to identify patients who may have a higher risk of developing cancer and identify actionable mutations to allow patients to receive targeted therapy and have their long-term treatment plan mapped out at diagnosis.

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of molecular testing in ovarian cancer.

Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.